Volume 26, Number 9—September 2020
Dispatch
Duration of Carbapenemase-Producing Enterobacteriaceae Carriage in Hospital Patients
Table
Characteristic |
No. (%) |
Sex | |
M | 15 (71.4) |
F |
6 (28.6) |
Ethnicity | |
Chinese | 15 (71.4) |
Malay | 3 (14.3) |
Indian | 2 (9.5) |
Other |
1 (4.8) |
Ambulatory status | |
Independently performs ADL | 12 (57.1) |
Requires assistance in ADL | 4 (19.0) |
Wheelchair bound | 3 (14.3) |
Bed bound |
2 (9.5) |
Recent surgery† |
15 (71.4) |
Colonization or infection with another MDRO in the year preceding enrollment | 4 (19.0) |
Hospitalization in past year | 11 (52.4) |
Antibiotic intake during follow-up period | 13 (61.9) |
Readmission during follow-up period | 10 (47.6) |
Recent overseas travel | 13 (61.9) |
*Median age (interquartile range) was 60.0 (50.0–69.0) y; median Charlson Morbidity Index (interquartile range) 3.0 (2.0–5.0). ADL, activities of daily living; MDRO, multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumanii, and carbapenem-resistant Pseudomonas aeruginosa, recorded from surveillance and clinical cultures taken in the year before study enrollment.
†Gastrointestinal surgeries (n = 7), skin and soft tissue surgeries (n = 4), neurosurgery (n = 2), removal of Tenckhoff catheter (n = 1), and urologic procedure (n = 1).
1These authors contributed equally to this article.
Page created: July 10, 2020
Page updated: August 19, 2020
Page reviewed: August 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.